<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733496</url>
  </required_header>
  <id_info>
    <org_study_id>PD-1104</org_study_id>
    <nct_id>NCT03733496</nct_id>
  </id_info>
  <brief_title>Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies</brief_title>
  <official_title>An Observational, Long-Term Extension Study for Participants in Prior VY-AADC01 Clinical Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurocrine Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Voyager Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Neurocrine Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An extension study for participants who have completed a prior VY-AADC01 clinical study&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 24, 2018</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>Up to 8 years from VY-AADC01 administration</time_frame>
    <description>Long-term safety of VY-AADC01 as measured by Adverse Events and Serious Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in AADC enzyme activity</measure>
    <time_frame>Up to 8 years from VY-AADC01 administration</time_frame>
    <description>Continued expression of AADC as measured by [18F]-fluorodopa (F-Dopa) positron emission tomography (PET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PD medications</measure>
    <time_frame>Up to 8 years from VY-AADC01 administration</time_frame>
    <description>Change from baseline in PD medications, measured as levodopa equivalent dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in motor function as assessed by Unified Parkinson's Disease Rating Scale (UPDRS)</measure>
    <time_frame>Up to 8 years from VY-AADC01 administration</time_frame>
    <description>Changes from baseline in motor function as assessed by UPDRS, in both &quot;Off&quot; and &quot;On&quot; medication states</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in &quot;Off&quot; and &quot;On&quot; time as recorded by the participant in Parkinson's Disease (PD) diary</measure>
    <time_frame>Up to 8 years from VY-AADC01 administration</time_frame>
    <description>Changes from baseline based on the PD Diary: &quot;OFF&quot; time; &quot;ON&quot; time without troublesome dyskinesia; &quot;ON&quot; time without dyskinesia; &quot;ON&quot; time with troublesome dyskinesia; and &quot;ON&quot; time with non-troublesome dyskinesia</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">23</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Participants from VY-AADC01 clinical studies:</arm_group_label>
    <description>Participants who have completed participation in VY-AADC01 clinical studies (PD-1101 or PD-1102) will be invited to participate in this extension study</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants from prior VY-AADC01 clinical studies will be eligible for the extension study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        1. Completed participation in the PD-1101 or PD-1102 clinical study of VY-AADC01 gene&#xD;
        therapy&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Grace Liang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Neurocrine Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Christine CW, Bankiewicz KS, Van Laar AD, Richardson RM, Ravina B, Kells AP, Boot B, Martin AJ, Nutt J, Thompson ME, Larson PS. Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. Ann Neurol. 2019 May;85(5):704-714. doi: 10.1002/ana.25450. Epub 2019 Mar 26.</citation>
    <PMID>30802998</PMID>
  </reference>
  <reference>
    <citation>Richardson RM, Bankiewicz KS, Christine CW, Van Laar AD, Gross RE, Lonser R, Factor SA, Kostyk SK, Kells AP, Ravina B, Larson PS. Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1210-1218. doi: 10.1136/jnnp-2020-322904. Epub 2020 Jul 30. Review.</citation>
    <PMID>32732384</PMID>
  </reference>
  <reference>
    <citation>Nutt JG, Curtze C, Hiller A, Anderson S, Larson PS, Van Laar AD, Richardson RM, Thompson ME, Sedkov A, Leinonen M, Ravina B, Bankiewicz KS, Christine CW. Aromatic L-Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease. Mov Disord. 2020 May;35(5):851-858. doi: 10.1002/mds.27993. Epub 2020 Mar 9.</citation>
    <PMID>32149427</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease (PD)</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Motor Fluctuations</keyword>
  <keyword>Neurosurgery</keyword>
  <keyword>NBIb-1817</keyword>
  <keyword>Aromatic L-Amino Acid Decarboxylase</keyword>
  <keyword>Levodopa</keyword>
  <keyword>Dopamine</keyword>
  <keyword>AADC</keyword>
  <keyword>DDC</keyword>
  <keyword>AAV2-hAADC</keyword>
  <keyword>AAV</keyword>
  <keyword>VY-AADC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

